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Background: Aging process is accompanied by a chronic sub-clinical systemic inflammation. This study aimed
to assess the association between hearing impairment and polymorphisms of genes encoding cytokines
deeply-committed to the inflammatory response and immune homeostasis in an elderly Japanese population. Data
were collected in the Longitudinal Study of Aging surveyed biennially between 1997 and 2010. The participants
without any missing information at baseline were 1,957 individuals, and the gross accumulated number of 8,675
subjects (40–89 years of age) was analyzed. Two hearing impairment criteria were taken as the better ear pure-tone
average (PTABE) greater than 25 dB and greater than 40 dB. We analyzed cumulative data using generalized estimating
equations to investigate the effect of 9 polymorphisms, namely, tumor necrosis factor (TNF) α, rs1800630; TNF receptor
super family (TNFRSF) 1B, rs1061624; interleukin (IL)-1A, rs1800587; IL-1B, rs16944; IL-4R, rs1801275; IL-6, rs1800796; IL-10,
rs1800872; IL-1 receptor-associated kinase 1 (IRAK1), rs1059702; C reactive protein (CRP), rs1130864.
Results: The odds ratios for the hearing impairment (PTABE >25 dB) risk under additive genetic model were significant
in TNF-α rs1800630 and TNFRSF1B rs1061624, which were respectively 1.172 (confidence interval [CI]: 1.005-1.367), 1.211
(CI: 1.053-1.392) in model after adjustment for possible confounders. Using the criterion of PTABE >40 dB as disabling
hearing impairment, the association remains significant in TNFRSF1B rs1061624, but not in TNF-α rs1800630. No other
polymorphisms showed a significant association.
Conclusions: The present population-based cohort study demonstrated that TNF-α rs1800630 and TNFRSF1B rs1061624
contributed to the incremental risk of hearing impairment in the elderly. TNF-α and TNF receptor interactions play a
pivotal role in the pathogenesis of the inflammatory response, and also cause programmed cell death and cell
proliferation. The present observation implied the signalling cascades of TNF were involved in ear aging.
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Chronic low-grade inflammation is the hallmark of the
aging process and is now accepted as a fundamental
pathogenic mechanism in the development of several
age-related degeneration including cardiovascular disease
[1], atherosclerosis [2], cognitive disorders [3], and type 2
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unless otherwise stated.The low-grade proinflammatory status appearing during
the aging process has become termed ‘inflammaging’,
coined by Franceschi et al. [5]. Physiological aging is
characterized by elevated levels of inflammatory mediators.
Serum pro-inflammatory cytokines such as interleukin
(IL)-6 and tumor necrosis factor (TNF) α and acute phase
proteins such as C-reactive protein (CRP) show an increase
with age [5]. Further, the levels of cytokines that counteract
the inflammatory state, such as IL-10, are reduced with
age [6] compounding the inability to maintain immune
homeostasis.
The subjects in the present analyses were derived from
the National Institute for Longevity Sciences - Longitudinal
Study of Aging (NILS-LSA), a population-based biennialLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dwellers. In the present study, we intended to clarify
the relationship between hearing impairment and nine
polymorphisms of genes encoding inflammatory media-
tors, namely, TNF-α C-863A, rs1800630; TNF receptor
superfamily member (TNFRSF) 1B G593A, rs1061624;
IL-1A -889C/T, rs1800587; IL-1B -511C/T, rs16944;
IL-4R G1902A, rs1801275; IL-6 C-572G, also known
as C-634G, rs1800796; IL-10 A-592C, rs1800872; IL-1
receptor-associated kinase 1 (IRAK1) T587C, rs1059702;
CRP +1444 C > T, rs1130864. Our ultimate aim is to get
closer to the pathophysiological elucidation of presbycusis
as an age-related disease.
Results and discussion
Table 1 shows the demographic profiles of the study
subjects at baseline and cumulative data. Of the 1957
participants at baseline, the mean age was 59.2 years, and
rates of male and hearing impairment with the World
Health Organization (WHO) criteria were 50.4% and
20.1%, respectively. Allelic and genotypic distribution of 9
single-nucleotide polymorphisms (SNPs) in subjects for
the present analyses at baseline are indicated in Table 2.
The results of multivariable analysis using logistic
regression with generalized estimating equations (GEEs)
were demonstrated in Table 3. Of the 9 SNPs analyzed,
there were significant associations of polymorphic alleles in
TNF-α and TNFRSF1B with risk increments for hearing
impairment, based on the criterion of PTABE >25 dB. The
odds ratios (ORs) for hearing impairment (PTABE >25 dB)
risk in TNF-α rs1800630 were 1.120 (95% confidence inter-
val [CI]: 0.979-1.281) in model 1, 1.192 (CI: 1.020-1.392) in






Sex, % male 50.4 51.5
Mean age (SD), year 59.2 (10.9) 62.0 (10.4)
Average hearing threshold for frequencies
0.5,1, 2, 4 kHz for the better ear (SD), dB
17.3 (12.0) 19.7 (12.1)
Hearing impairment with the
WHO criteria, %
20.1 25.0
Ear disease history, % 27.4 30.2
Occupational noise exposure, % 22.8 21.4
Hypertension, % 24.9 29.6
Diabetes, % 7.5 8.2
Dyslipidemia, % 16.7 19.7
Stroke, % 2.6 3.8
Cardiac disease, % 11.8 13.4
Smoking, % 44.2 43.2in TNFRSF1B rs1061624 were 1.151 (CI: 1.021-1.297) in
model 1, 1.210 (CI: 1.052-1.393) in model 2, and 1.211 (CI:
1.053-1.392) in model 3. The significance was still observed
even after adjustment for possible confounders in model 3.
Using the criterion of PTABE >40 dB as disabling hearing
impairment, the association between polymorphic allele
and hearing impairment remain significant in TNFRSF1B
rs1061624, but not in TNF-α rs1800630. The ORs for
hearing impairment (PTABE >40 dB) risk in TNFRSF1B
rs1061624 were 1.272 (CI: 1.052-1.538) in model 1, 1.293
(CI: 1.045-1.599) in model 2, and 1.275 (CI: 1.026-1.584)
in model 3.
In the other 7 SNPs, no significant risks of hearing
impairment in either criterion were observed in models
with different combination of moderator variables.
In the present study, we assessed the contribution of
polymorphic genes encoding inflammatory mediators to
hearing loss in an elderly Japanese community-dwelling
population. The results suggested that TNF-α rs1800630
and TNFRSF1B rs1061624 may be involved in risk incre-
ment of age-related hearing impairment. The significant
ORs observed both in two hearing impairment criteria
implied a substantial impact of TNFRSF1B rs1061624 on
the susceptibility of age-related hearing impairment,
since hearing impairment of the better ear means bilat-
eral impairment and thus WHO defines disabling hear-
ing impairment.
TNF-α is a proinflammatory cytokine that is a master
regulator of vascular proatherogenic changes and the
pathogenesis of inflammatory diseases [7]. It serves a
function in the regulation of cell differentiation, prolifer-
ation and apoptosis, also in inflammation, innate and
adaptive immune responses. TNF-α does not work inde-
pendently at the cellular level. It activates intracellular
signaling cascades via binding to two types of receptors,
TNF receptor superfamily member 1A (TNFRSF1A/ also
known as p55 andTNFR1) and member 1B (TNFRSF1B/
also known as p75 and TNFR2), then exerts its pleiotropic
role. TNFRSF1A is expressed on most human cell types,
while TNFRSF1B expression is restricted to certain
subpopulations of specific neuronal subtypes, endothelial
cells, and cells of the immune system [8,9].
Many researchers have substantiated emergence of
TNF-α and other mediators in the inflammatory response
of inner ear. TNF-α is secreted mainly by activated macro-
phages, monocytes, T cells, B cells, and fibroblasts [10]. In
the cochlea, it is reported that spiral ligament fibrocytes
have been shown to release chemokines including TNF-α
when challenged with otitis media pathogens [10]. Other
authors have reported the role of inflammatory cytokines,
particularly TNF-α, in inner ear inflammation [11-13].
Studies using immunohistological and genetic amplification
analyses from University of Debrecen in Hungary reported
that elevated TNF-α receptor expression correlates with
Table 2 Allelic and genotypic distribution of subjects for the present analyses at baseline
Gene rs No Allele1) Allele N= 3914 Number (%) Genotype N= 1957 Number (%)
Tumor necrosis factor-α (TNF-α) rs1800630 A (C) C A CC CA AA
3229 (82.5) 685 (17.5) 1420 (72.5) 389 (19.9) 148 (7.6)
Tumor necrosis factor receptor
superfamily member 1B (TNFRSF1B)
rs1061624 A (G) G A GG GA AA
1916 (49.0) 1998 (51.0) 473 (24.2) 970 (49.6) 514 (26.2)
Interleukin-1A (IL1A) rs1800587 T (C) C T CC CT TT
3525 (90.1) 389 (9.9) 1587 (81.1) 351 (17.9) 19 (1.0)
Interleukin-1B (IL1B) rs16944 T (C) C T CC CT TT
2094 (53.5) 1820 (46.5) 546 (27.9) 1002 (51.2) 409 (20.9)
Interleukin 4 receptor (IL-4R) rs1801275 G (A) A G AA AG GG
3375 (86.2) 539 (13.8) 1454 (74.3) 467 (23.9) 36 (1.8)
Interleukin-6 (IL-6) rs1800796 G (C) C G CC CG GG
2969 (75.9) 945 (24.1) 1134 (58.0) 701 (35.8) 122 (6.2)
Interleukin-10 (IL-10) rs1800872 C (A) A C AA AC CC
2648 (67.7) 1266 (32.3) 896 (45.8) 856 (43.7) 205 (10.5)
Interleukin 1 receptor-associated kinase-1 (IRAK-1) rs1059702 C (T) T C TT TC CC
3000 (76.6) 914 (23.4) 1312 (67.0) 376 (19.2) 269 (13.8)
C-reactive protein 2 (CRP2) rs1130864 T (C) C T CC CT TT
3670 (93.8) 244 (6.2) 1721 (87.9) 228 (11.7) 8 (0.4)
1)Reference alleles are indicated in parentheses.
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that histologic otosclerosis exhibits a strong correlation
with measles virus presence in the bone and related
inflammation with TNF-α and speculated that the TNF-α
chronically released from the foci enters the inner ear fluid
spaces in histologically active stages of otosclerosis and
may cause outer hair cell functional disorder and subse-
quent sensorineural hearing loss [15].
Recently inflammatory responses in inner ear under vari-
ous damaging conditions including noise-overstimulation
have been reported [16,17]. Fujioka, et al. evaluated the
time-dependent expression of proinflammatory cytokines
in noise-exposed rat cochlea, and suggested that proin-
flammatory cytokines, including TNF-α, IL-1 β, and IL-6
might initiate an inflammatory response and could have
some role in the mechanism of noise-induced cochlear
damage. Hwang, et al. evaluated tinnitus and mRNA
expression levels of TNF-α, IL-1β, and N-methyl D-
aspartate receptor subunit 2B (NR2B) genes in cochlea
and inferior colliculus of mice after intraperitoneal injec-
tions of salicylate, then concluded that salicylate treatment
resulting in tinnitus augmented expression of the TNF-α,
IL-1 β genes in cochlea and inferior colliculus [18].
One study in experimental animals demonstrated that
the use of a TNF-α-neutralizing agent could prevent
the sensorineural hearing loss secondary to induced
pneumococcal meningitis [19]. Meanwhile, the potential
cytotoxicity of TNF-α, itself on cochlear sensory cells isopen to debate. Keithley, et al. tested for circulating leuko-
cytes recruitment induced by TNF-α in the guinea pig
inner ear and examined hair cells in culture directly
exposed to TNF-α [20]. TNF-α infused into the guinea pig
cochlear scala tympani in the absence of antigen or patho-
gens resulted in infiltration of leukocytes around the
venules and within scala tympani. In their interpretation,
TNF-α is sufficient to recruit inflammatory cells to the
cochlea. However, there was no associated hearing loss as
measured with a click stimulus. And TNF-α at concentra-
tions used in the in-vivo experiments applied directly to
organ of Corti explants caused minimal hair cell death.
They concluded that the profound hearing loss and severe
loss of inner hair cells observed in antigen-induced laby-
rinthitis cannot be explained by direct TNF-α mediated
cytotoxicity alone.
Through extensive examinations of expression and func-
tion, some genetic variations have been shown to explain
inter-individual variation. SNPs in the TNF-α, TNFRSF1A
and TNFRSF1B genes have been identified, however func-
tional data pertaining to these polymorphisms in scarce.
Rs1800630 is a common functional polymorphism, involv-
ing a C to A substitution at position −863. It is located in
the proximal promoter of the TNF-α gene. The presence of
DNA sequence variations in regulatory region might inter-
fere with transcription of TNF-α gene, and with increase in
the susceptibility to human wide range of diseases (infec-
tious, cancer, autoimmune, neurodegenerative and other
Table 3 Hearing impairment risk of inflammatory mediators related SNPs analyzed using logistic regression with
generalized estimating equations
Gene rs No Crude: model 1 Adjusted: model 2 Adjusted: model 3




PTABE 1)>25 dB 1.120 0.979-1.281 0.100 1.192 1.020-1.392 0.027 1.172 1.005-1.367 0.044
PTABE 40 dB 1.090 0.885-1.344 0.417 1.109 0.884-1.390 0.372 1.106 0.884-1.384 0.380
TNFRSF1B rs1061624
PTABE >25 dB 1.151 1.021-1.297 0.022 1.210 1.052-1.393 0.008 1.211 1.053-1.392 0.007
PTABE >40 dB 1.272 1.052-1.538 0.013 1.293 1.045-1.599 0.018 1.275 1.026-1.584 0.028
IL1A rs1800587
PTABE >25 dB 1.093 0.894-1.335 0.386 1.061 0.845-1.331 0.611 1.070 0.855-1.339 0.557
PTABE >40 dB 0.975 0.692-1.373 0.885 0.946 0.660-1.354 0.760 0.956 0.667-1.371 0.807
IL1B rs16944
PTABE >25 dB 0.941 0.834-1.060 0.316 0.915 0.796-1.052 0.212 0.920 0.801-1.057 0.238
PTABE >40 dB 0.924 0.762-1.121 0.422 0.960 0.774-1.190 0.706 0.945 0.760-1.174 0.608
IL-4 Rrs1801275
PTABE >25 dB 0.986 0.829-172 0.872 1.038 0.851-1.265 0.715 1.031 0.847-1.255 0.761
PTABE >40 dB 0.968 0.729-1.85 0.822 1.010 0.746-1.367 0.949 1.050 0.774-1.424 0.756
IL-6 rs1800796
PTABE >25 dB 1.011 0.881-1.161 0.872 1.083 0.924-1.269 0.327 1.079 0.922-1.262 0.343
PTABE >40 dB 1.034 0.829-1.289 0.770 1.042 0.822-1.320 0.734 1.056 0.833-1.339 0.651
IL-10 rs1800872
PTABE >25 dB 0.981 0.864-1.114 0.764 0.983 0.844-1.145 0.826 0.973 0.838-1.131 0.725
PTABE >40 dB 0.887 0.714-1.102 0.280 0.860 0.572-1.101 0.231 0.834 0.651-1.070 0.153
IRAK-1 rs1059702
PTABE >25 dB 1.026 0.912-1.55 0.666 1.012 0.889-1.151 0.862 1.010 0.888-1.148 0.885
PTABE >40 dB 0.887 0.718-1.097 0.268 0.8161 0.707-1.051 0.141 0.869 0.713-1.058 0.162
CRP2 rs1130864
PTABE >25 dB 0.976 0.758-1.257 0.81 1.099 0.816-1.479 0.535 1.092 0.817-1.461 0.552
PTABE >40 dB 0.924 0.624-1.363 0.692 1.081 0.711-1.643 0.715 1.113 0.726-1.705 0.623
1)PTABE : pure-tone average threshold at 0.5, 1, 2 and 4 kHz for the better ear.
Moderating variables.
model 1 : No variables.
model 2 : Age and sex.
model 3 : Any history of noise exposure, ear disease, hypertension, diabetes, dyslipidemia, stroke and cardiac disease, and lifetime smoking habit in addition to those of model 2.
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morphism and disease prevalence comprehensively [7].
In the review, several mechanisms playing important role
in gene regulation were discussed. Two most important
factors that interfere with the gene regulation are promoter
hypermethylation and the presence of polymorphism in
regulatory region, and their hypothesis was that during dis-
ease conditions, there was upregulation or downregulation
of gene (transcriptional dysregulation). TNF-α polymorph-
ism rs1800630 A-allele was associated with lower specific
anti-pneumococcal IgG levels compared with children
carrying C⁄C genotype of rs1800630, in one instance [7].In the present analyses, significant odds ratios for hearing
impairment risk were obtained even after adjustment
for possible influential variables. The minor A-allele of
rs1800630 polymorphism increased the risk of hearing
impairment.
There are limited data regarding the functionality of the
various SNPs in the TNFRSF1B gene. One clinical cancer
investigation demonstrated that the TNFRSF1B rs1061624
genotype was a predictive factor of clinical response i.e.,
a complete response or not, to treatment with a 5-
fluorouracil (5-FU)/cisplatin (CDDP) - based chemoradio-
therapy in Japanese esophageal squamous cell carcinoma
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to affect the phenotype of inflammatory bowel diseases in
a New Zealand Caucasian population (decreased the risk
of ulcerative colitis in the left colon) [22]. In our results,
TNFRSF1B rs1061624 was associated with risk increment
of age-related hearing impairment defined as a hearing
level of PTABE >25 dB and PTABE >40 dB.
Recently, we found a significant association of risks
for both sudden sensorineural hearing loss (SSNHL)
and Ménière’s disease with IL-1A rs1800587 polymorph-
ism [23], and also reported that carriers of the IL-6
rs1800796 minor-allele were potentially more susceptible
to SSNHL than noncarriers [24]. From one Korean
case–control investigation, the presence of the IL-4R
polymorphism Q576R, also known as G1902A, rs1801275
[25], was reported to be a risk factor for SSNHL [26].
In the present results, however, no associations of the
presence of the 7 SNPs other than TNF-α rs1800630
and TNFRSF1B rs1061624, were found with the risk of
age-related hearing impairment.
Several potential limitations of the present study should
be cited. The genes in the selection of the present analyses
were highly polymorphic respectively. To cite an example,
32 SNPs lies in transcription factor–binding site of 20
transcription factors have been detected in the TNF-α
upstream region [7]. But restrictions in budget and effi-
ciency allowed us only to investigate widely and shallowly.
Selection criterion of SNPs in the NILS-LSA study was
based on candidate polymorphisms analysis for aging or
geriatric diseases, such as senescence, geriatric syndrome,
dementia, and osteoporosis. We focused the association
between candidate SNPs for aging and hearing, then pre-
viously published the effects on hearing in the elderly, of
EDN1, MTHFR, MTR (folate metabolism), UCP1, UCP2,
and FABP2, oxidative stress related SNPs [27-30].
In addition, we were not able to obtain each inflamma-
tory cytokine level in individuals. However, recent experi-
mental observation, which explored the cochlear cytokine
expression pattern under normoxia and hypoxia, suggested
presence of tissue-specific regulatory pathways even among
three different cochlear tissues; the organ of Corti, stria
vascularis together with spiral ligament, and modiolus [31].
Given the tissue-specificity of cochlear tissue, even if blood
cytokine level during common condition is obtained, it
cannot be directly linked to pathogenetic elucidation.
Further basic and applied researches will be required to
interpret the role of each SNP in hearing deterioration.
From the aspect of methodology, there may be some
other way to define a criterion for hearing impairment
by different age groups, such as comparison with normal
hearing levels according to the International Organization
for Standardization (ISO) standard 7029:2000 [32]. ISO-
7029 is based on a linear model of the hearing threshold
for populations of otologically normal persons within theage limits of 18 years to 70 years, not including the older
ages. Because the age range of the present subjects was
distributed up to 89 years of age, we did not use a hearing
assessment according to the ISO-7029.
The strength of this study is found in a feature of the
NILS-LSA subject group. The NILS–LSA cohort consists
of inhabitants who were selected randomly from resident
registrations and stratified according to both age and sex.
The risk of genotypic bias in subjects was therefore likely
to be minimal. There were no significant differences in
genotype frequencies of TNF-α rs1800630 and TNFRSF1B
rs1061624 between the HapMap-JPT values and those
obtained for the current participants. The ancestral allele
of the rs1061624 single nucleotide variation is A-allele.
The reference allele in the present analyses was G-allele,
and G-allele frequencies of the rs1061624 polymorphism
were released in the frequency reports as 0.535 in
HapMap-JPT (Japanese in Tokyo), 0.539 in 1000 Genomes
Project JPT (Japanese in Tokyo), 0.390 in AoD_Japanese,
0.507 in JBIC-allele (752 anonymous unrelated Japanese
volunteers), and 0.580 in JPT_GENO_PANEL.
Conclusion
The present population-based cohort study demonstrated
that TNF-α rs1800630 and TNFRSF1B rs1061624 contrib-
uted to the incremental risk of hearing impairment in the
elderly Japanese population. TNF-α and TNF receptor
interactions play a pivotal role in the pathogenesis of
the inflammatory response, and also cause programmed
cell death and cell proliferation. The present observation
implied that the signaling cascades of TNF-α were involved
in age-related hearing loss.
Materials and methods
Subjects
The NILS-LSA is a comprehensive and interdisciplinary
study to observe age-related changes and consists of
various gerontological and geriatric measurements, such
as medical examinations, blood chemical analysis, body
composition, anthropometry, physical function, nutritional
analysis, psychological tests, and visual and auditory func-
tion. The participants were community-dwelling adults
of Aichi Prefecture in central Japan, who were randomly
selected from resident registrations, stratified by both age
and sex in cooperation with the local government. The
numbers of men and women recruited were similar, and
age at baseline was 40 years to 79 years, with similar
numbers of participants in each decade of age (40s, 50s,
60s, and 70s). Most of medical check-up are examined
repeatedly every two years, and venous blood samples for
genetic test were collected only at the first-wave examin-
ation. Sera and DNA samples were stored in deep freezers
for later examination. The study protocol was approved
by the Committee of Ethics of Human Research of the
Table 4 PCR conditions used in genotyping the inflammatory gene variants
Gene rs No Labeled primers Sequence(5'→3') Amplicon (F1/R)/(F2/R) (bp) Annealing temp.(°C) Mg(mM)
Tumor necrosis factor-α (TNF-α) rs1800630 F1(FITC) ATG GCC CTG TCT TCG TTA AxT G 75/77 62.5 3
F2(Texas Red) GGC CCT GTC TTC GTT AAx GG
R(Biotin) ACA GCA ATG GGT AGG AGA ATG TC
Interleukin-1A (IL1A) rs1800587 F1(FITC) AATAATAGTAACCAGGCAACxTC 91/92 60 2.5
F2(Texas Red) TAATAATAGTAACCAGGCAACxCC
R(Biotin) AGTGGCTAAGTTTGGGAATGG
Interleukin-1B (IL1B) rs16944 F1(FITC) GGTGCTGTTCTCTGCCTxGG 50 60 1.5
F2(Texas Red) GGTGCTGTTCTCTGCCTxAG
R(Biotin) TCAGAGGCTCCTGCAATTGAC
Interleukin 4 receptor (IL-4R) rs1801275 F1(FITC) GCC CCC ACC AGT GGC TAT xGG 49/50 67.5 2.8
F2(Texas Red) GGC CCC CAC CAG TGG CTA TxA G
R(Biotin) CAC CCT GCT CCA CCG CAT GTA
Interleukin-6 (IL-6) rs1800796 F1(FITC) GGC AGT TCT ACA ACA GCx CC 43/42 60 1.5
F2(Texas Red) GCA GTT CTA CAA CAG CxG C
R(Biotin) CTG TGT TCT GGC TCT CCC TG
Interleukin-10 (IL-10) rs1800872 F1(FITC) CAG AGA CTG GCT TCC TAC AxG A 51/53 62.5 2.5
F2(Texas Red) CCA GAG ACT GGC TTC CTA CAx TA
R(Biotin) GCC TGG AAC ACA TCC TGT GA
Interleukin 1 receptor-associated
kinase-1 (IRAK-1)








rs1061624 F CCC TCT GAC CTG CAG GCC AAG 61 65 2 AGC AGA GGC AGC GAG TTG
R CCA TGG CAG CAG AGG CTT TCC
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#52, #74). Written informed consent was obtained from
all participants. The details of the NILS-LSA have been
described elsewhere [30,33].
Data were collected from the NILS-LSA participants
who partook at least in the first-wave examination.
Those who did not consent to have blood samples taken,
and those who lacked results for any of the nine SNP
genotype analyses were excluded. The participants at
baseline were 2,149 adults, and the cumulative data were
9,358 samples in accumulated total, which were com-
piled from the first through the sixth-wave examination
surveyed between 1997 and 2010. Participants filled out
a series of questionnaires in advance of the examination
visit. Ear disease history and experience of occupational
noise exposure were taken account as basic informations
in an evaluation of age-related hearing impairment.Table 5 Genotype distribution of participants at first-wave ex
criteria, and comparison with those of HapMap-JPT or anothe
Gene rs No Allele1)
TNF-α rs1800630 A (C)
Our baseline subjects
HapMap-JPT
TNFRSF1B rs1061624 A (G)
Our baseline subjects
HapMap-JPT
IL1A rs1800587 T (C)
Our baseline subjects
HapMap-JPT
IL1B rs16944 T (C)
Our baseline subjects
PGA-UW-FHCRC: JPT_GENO_PANEL2)
IL-4R rs1801275 G (A)
Our baseline subjects
HapMap-JPT
IL-6 rs1800796 G (C)
Our baseline subjects
HapMap-JPT
IL-10 rs1800872 C (A)
Our baseline subjects
HapMap-JPT
IRAK-1 rs1059702 C (T)
Our baseline subjects
HapMap-JPT
CRP2 rs1130864 T (C)
Our baseline subjects
HapMap-JPT
1)Reference alleles are indicated in parentheses.
2)Variation Discovery Resource. A collaboration between the University of WashingtHistories of hypertension, diabetes, dyslipidemia, stroke,
and cardiac disease were also taken from the self-reported
account. Lifetime smoking history was categorized as
never or ever. Those who had a deficiency of any required
information for the present analyses and those who did
not complete the hearing test were excluded. The subjects
for the present analyses without any missing information
were 1,957 individuals at baseline, and the gross accumu-
lation number of subjects, regardless of repetitive visits,
was 8,675 adults 40 years to 89 years of age. The mean
number of repetitive visits was 4.4.
Genetic analyses and other measures
Genomic DNA was extracted from peripheral blood lym-
phocytes using the standard procedure and polymerase
chain reaction (PCR) amplification was performed. Nine
polymorphisms of genes encoding inflammatory mediators,aminations of NILS-LSA before application of exclusion
r public database
Genotype N= 2149, Number (%) p-value
CC CA AA
































1889 (87.9) 251 (11.7) 9 (0.4)
NS
(87.2) (11.6) (1.2)
on and the Fred Hutchinson Cancer Research Center.
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http://www.immunityageing.com/content/11/1/18namely, TNF-α C-863A, rs1800630; TNF receptor
superfamily member (TNFRSF) 1B G593A, rs1061624;
IL-1A -889C/T, rs1800587; IL-1B -511C/T, rs16944; IL-4R
G1902A, rs1801275; IL-6 C-572G, also known as C-634G,
rs1800796; IL-10 A-592C, rs1800872; IL-1 receptor-
associated kinase 1 (IRAK1) T587C, rs1059702; CRP +1444
C >T, rs1130864 were investigated.
Genotyping was carried out using a fluorescence method
and melting curve method. Details including of primer
sequences and PCR conditions are listed in Table 4.
Genotype distributions of 9 SNPs in participants at first-
wave examinations of NILS-LSA before application of
exclusion criteria are shown in Table 5. There were no
significant differences between genotypic frequencies of
our participants and public database samples but in IL-4R
and IL-6 (chi-square test, level of significance: 0.05).
Air-conduction pure-tone thresholds at octave intervals
from 0.5 kHz to 8 kHz were measured in a sound-proof
booth by trained examiners using a standardized protocol
and a diagnostic audiometer (AA-73A and AA-78; Rion,
Tokyo, Japan). The pure-tone average threshold level of
the better ear at frequencies of 0.5, 1, 2, and 4 kHz
(PTABE) was used as an index of hearing status. Hearing
impairment was defined as a PTABE greater than 25 dB
according to WHO grades [34]. The WHO defines disab-
ling hearing impairment in adults as a permanent unaided
PTABE of 41 dB or greater. In view of this, we adopted
two hearing impairment criteria for the statistical analyses;
PTABE >25 dB and PTABE >40 dB.
Statistical analyses
Statistical analyses were conducted using the Statistical
Analysis System (SAS) version 9.1.3 (SAS Institute, Cary,
NC, USA). For univariate analysis, a t-test was used to
assess differences of continuous variables between two
groups, and comparisons of categorical variables were
performed using the chi-square test. Fisher’s exact test
was also used, as and when the number of cell samples
was less than five. Unless otherwise noted, values are
expressed as mean ± standard deviation.
Cumulative data were analyzed using GEEs, which take
into account the dependency of repeated observations
within subjects. GEE is a common statistical model to
analyze epidemiological longitudinal data. GEE models
were fitted using the GENMOD procedure of Statistical
Analysis System version 9.1.3. The GENMOD procedure
fits generalized linear models. The correlation structure
was specified as autoregressive. We took mode of inherit-
ance in analyses as additive genetic model, which is the
prevailing analytical model in genetic epidemiology,
assumes that there is a linear gradient in risk with
increasing numbers of variant alleles (reference allele
homozygotes base). ORs for the additive genetic models
of 9 SNPs with the risk of hearing impairment wereanalyzed. As a combination of moderator variables, three
models were analyzed. In model 1, no moderator variables
were adjusted; in model 2, age and gender were taken as
moderator variables; and in model 3, any history of noise
exposure, ear disease, hypertension, diabetes, dyslipidemia,
stroke and cardiac disease, and lifetime smoking habit was
adjusted in addition to age and gender.
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